Antiviral Drugs for Cats: FIP and Herpesvirus Treatments

Antiviral drugs for cats have gone from essentially nonexistent to genuinely life-saving in under a decade, driven largely by a single molecule called GS-441524 that turned feline infectious peritonitis from a death sentence into a treatable disease. A systematic review covering 650 cats with FIP found an overall treatment success rate of about 85% with GS-441524 alone or in combination with other antivirals. But FIP is not the only feline viral illness, and GS-441524 is not the only antiviral that matters. Cats face herpesvirus, calicivirus, feline leukemia virus, and feline immunodeficiency virus, and the antiviral options for each of these look very different in terms of effectiveness, safety, and availability.

GS-441524 and the FIP Revolution

Feline infectious peritonitis was, until recently, considered uniformly fatal. The disease starts when a common and usually harmless feline coronavirus mutates inside a cat’s body, triggering a devastating immune-mediated inflammatory response. GS-441524, an adenosine analogue that blocks viral replication, changed everything. In the earliest published trial of 31 cats with naturally occurring FIP, 25 became long-term survivors after one or more rounds of treatment, with the optimal dose found to be 4.0 mg/kg given subcutaneously once daily for at least 12 weeks.¹ That initial study was small, but the results have held up at scale. A 2024 systematic review pooling 11 studies and 650 FIP cases reported an overall success rate of about 85%, with better outcomes when GS-441524 was combined with other antivirals and worse outcomes in cats with the wet (effusive) form or neurological involvement.²

That 85% figure is remarkable for a disease that used to kill virtually every cat it affected. The dosages associated with the best outcomes fall in the range of 5 to 10 mg/kg once daily, adjusted upward for cats with neurological or ocular signs. In the original trial, cats that relapsed on a lower dose often responded when the dose was bumped up, and higher-dose retreatment rescued several cats that would otherwise have been lost. The typical treatment course runs 12 weeks, though some cats need longer, and relapses can occur weeks to months after stopping.

Molnupiravir as a Second-Line FIP Drug

Molnupiravir, the oral antiviral that gained attention during the COVID-19 pandemic, has also shown real promise against FIP. In a case series of 18 cats treated with an off-label compounded formulation, 14 achieved remission with rapid clinical improvement. Fever and appetite typically bounced back within two to three days, and none of the 14 responders had relapsed during follow-up periods of roughly two to three and a half months.³ A larger study of 54 cats found that molnupiravir monotherapy cured about 72% of cases, molnupiravir maintenance therapy achieved an 86% cure rate, and when used as a rescue therapy after other treatments, it cured all seven cats that received it.⁴

One practical advantage of molnupiravir is that it can be given orally, which matters a lot when you are asking a cat owner to administer medication daily for months. GS-441524 was originally studied as a subcutaneous injection, and while oral formulations now exist, molnupiravir gives veterinarians a useful alternative. The 54-cat study found no significant difference in outcomes between cats treated with molnupiravir and those treated with remdesivir or GS-441524, suggesting these drugs are broadly comparable in effectiveness for FIP.

How Cat Owners Actually Get These Drugs

For years, GS-441524 existed in a legal gray zone. It was clearly effective, but no pharmaceutical company had taken it through formal approval for veterinary use, so cat owners were sourcing it from overseas compounding labs and black-market suppliers. The situation has improved significantly in the United States, where the FDA now permits compounding pharmacies operating under section 503A to prepare GS-441524 from bulk drug substances. Under federal guidance, veterinarians can prescribe it for their patients, and in most states the drug can even be kept as office stock without a patient-specific prescription.⁵ No FDA-approved product exists yet, but the regulatory pathway is now clear enough that most veterinary clinics can obtain and prescribe the drug legally.

Cost remains a real barrier. A 12-week course of treatment can run into the thousands of dollars depending on the cat’s weight, the dose required, and the formulation used. Cats with neurological FIP need higher doses for longer, pushing costs further. Still, “expensive but available” is a world apart from “untreatable,” which is where FIP stood just a few years ago.

Famciclovir and Feline Herpesvirus

Feline herpesvirus type 1 (FHV-1) is one of the most common viruses in cats, responsible for sneezing, runny eyes, corneal ulcers, and chronic upper respiratory flare-ups. Most cats pick it up as kittens, and the virus hides in nerve tissue for life, reactivating during stress. The antiviral most commonly prescribed for FHV-1 is famciclovir, a drug originally developed for human herpes infections. Cats convert famciclovir to its active form, penciclovir, though the pharmacokinetics are unusual. A study of famciclovir at multiple oral doses in healthy cats found that bioavailability actually dropped as the dose increased, falling from about 67% at the lowest dose tested down to roughly 18% at the highest.⁶ This nonlinear absorption pattern means simply giving a bigger pill does not proportionally increase how much active drug reaches the bloodstream.

Despite widespread use, the clinical evidence for famciclovir in naturally occurring feline upper respiratory disease is surprisingly thin. A study of cats with spontaneous acute upper respiratory infections found no significant difference in improvement between cats treated with famciclovir plus doxycycline and those treated with doxycycline alone. Both groups improved quickly. The researchers noted that FHV-1 DNA was detected in relatively few of the enrolled cats, which may have diluted any antiviral benefit, since famciclovir would not help cats whose symptoms were caused by bacteria or calicivirus rather than herpesvirus.⁷ In practice, many veterinarians still prescribe famciclovir for cats with confirmed or strongly suspected FHV-1, particularly those with corneal disease, where the stakes of not treating are higher.

Cidofovir for Herpesvirus Eye Disease

When FHV-1 targets the eyes, causing dendritic ulcers or stromal keratitis, topical antiviral treatment becomes important. Cidofovir, applied as eye drops, has shown efficacy in experimentally infected cats. Twice-daily application of a 0.5% cidofovir solution significantly reduced both the amount of virus shed from the eyes and the severity of clinical disease compared to untreated controls.⁸ The advantage of cidofovir over older topical options like idoxuridine or trifluridine is convenience: it needs to be applied only twice a day rather than five or six times, which makes a real difference for owner compliance and for the cat’s tolerance.

Cidofovir is typically compounded by veterinary pharmacies, since the commercial human formulation is an intravenous product not suitable for direct ophthalmic use in cats. Like most herpesvirus treatments, it manages flare-ups rather than eliminates the latent infection. Once the acute episode resolves, the virus retreats back into nerve tissue to await the next stressor.

The Lysine Myth

L-lysine supplements are still widely recommended for cats with FHV-1, sold at pet stores and even dispensed by some veterinary clinics. The idea is that lysine competes with arginine, an amino acid the herpesvirus needs to replicate. The problem is that this does not actually work. A systematic review of the available evidence concluded that lysine supplementation is not effective for the prevention or treatment of FHV-1 infection in cats.⁹ Some studies have even suggested that lysine supplementation could worsen outcomes. Despite this, the recommendation persists in many corners of veterinary practice and in countless online forums. If you are spending money on lysine for your cat’s herpesvirus, that money would be better spent elsewhere.

Interferon Omega for FeLV and FIV

Feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) are retroviruses that suppress the immune system over time, leaving cats vulnerable to secondary infections, anemia, and cancer. There is no antiviral cure for either virus, but recombinant feline interferon omega (rFeIFN-ω) has been studied as a way to reduce symptoms and extend survival. In a placebo-controlled trial of cats symptomatic with FeLV or FeLV/FIV coinfection, interferon-treated cats had significantly better clinical scores during the first four months and lower mortality rates at nine and twelve months. Controls had a 1.7 times higher risk of death at nine months compared to the interferon group.¹⁰

For cats with FIV alone, the picture is less clear. A review of the available studies found that while each reported reduced clinical signs with interferon treatment, all had limitations in design and statistical analysis. The overall evidence for interferon omega in FIV-positive cats was rated as weak.¹¹ Interferon omega is licensed in some countries (it is available in Europe and parts of Asia) but not in the United States, which limits access for many cat owners. It is also expensive and requires a course of subcutaneous injections.

Zidovudine (AZT), borrowed from human HIV treatment, has been used in FIV-positive cats, but its utility is limited by a well-known side effect: it can cause non-regenerative anemia, where the bone marrow stops producing enough red blood cells. Cats on AZT need regular blood monitoring, and the drug is generally reserved for cats with active clinical disease rather than used prophylactically.

Why Some Human Antivirals Are Dangerous for Cats

Cats metabolize drugs differently than humans and dogs. They have reduced capacity for a key liver detoxification pathway called glucuronidation, which means drugs that rely on that pathway can linger at toxic levels. Ribavirin is the cautionary tale. In cats given ribavirin at doses ranging from 11 to 44 mg/kg daily, the drug caused severe bone marrow toxicity, particularly destroying platelet-producing cells. Platelet counts dropped by 33 to 78% at the moderate and high doses. Cats also developed weight loss, appetite loss, diarrhea, liver enzyme elevations, and intestinal inflammation.¹²

When ribavirin was actually tested as a treatment for feline calicivirus, the results were alarming. Rather than helping, the drug made infected cats worse. The treated group had more severe clinical signs than untreated cats, largely because of hemorrhage caused by the profound thrombocytopenia the drug induced.¹³ Ribavirin is essentially contraindicated in cats. This is a useful reminder that a drug being “antiviral” does not make it safe for every species, and human medications should never be given to cats without veterinary guidance.

Feline Calicivirus and the Search for Treatments

Feline calicivirus (FCV) causes oral ulcers, upper respiratory signs, and occasionally a severe systemic form called virulent systemic FCV that can kill even vaccinated cats. Compared to FIP and herpesvirus, the antiviral pipeline for calicivirus is earlier-stage, but a few candidates have emerged. GC376, a protease inhibitor originally developed as a broad-spectrum antiviral, showed inhibitory activity against the FCV protease in lab assays, with about 75% inhibition at the tested concentration.¹⁴ GC376 has also demonstrated broad activity against both feline coronavirus and calicivirus proteases in cell culture, suggesting it could eventually serve double duty.¹⁵

In a more surprising finding, mefloquine, an antimalarial drug, showed strong inhibition of calicivirus replication in cell culture. It worked against both a reference lab strain and seven recent field isolates from Australia, and its effect was enhanced when combined with recombinant feline interferon omega.¹⁶ These are lab results, not clinical cures. No antiviral is currently approved or widely used for treating calicivirus in cats. Treatment remains supportive: fluids, nutrition support, pain management for oral ulcers, and antibiotics for secondary bacterial infections.

Combination Therapy and What Comes Next

As with HIV treatment in humans, there is growing interest in combining antivirals for feline diseases rather than relying on a single drug. Laboratory work has tested combinations of nucleoside analogues (like GS-441524 and molnupiravir) with protease inhibitors (like GC376 and nirmatrelvir) against feline coronavirus. Some combinations showed synergistic effects in cell culture, meaning the drugs together performed better than either alone. Pharmacokinetic testing in cats confirmed that oral doses of molnupiravir at 10 mg/kg, GS-441524 at 25 mg/kg, and remdesivir at 25 mg/kg all achieved blood levels above the concentrations needed to inhibit the virus. For GS-441524 and remdesivir, those levels were sustained over a full 24 hours.¹⁷ The systematic review of GS-441524 noted that success rates were higher when it was combined with other antivirals, consistent with the idea that combination therapy may reduce relapses and improve outcomes for difficult cases.¹⁸

Combination approaches are especially relevant for the cases where single-drug therapy falls short: neurological FIP, ocular FIP, and cats that relapse after an initial treatment course. Whether multi-drug protocols become standard will depend on clinical trials that are still being designed and run.

Monoclonal Antibodies on the Horizon

Beyond small-molecule drugs, researchers are developing monoclonal antibodies tailored to feline viruses. These are lab-made proteins designed to latch onto a virus and neutralize it. A chimeric rabbit-feline antibody targeting feline parvovirus (the cause of panleukopenia, a severe and often fatal disease in kittens) protected cats from illness when given after viral challenge. Treated cats survived without clinical signs, and their white blood cell counts, body temperatures, and diarrhea all returned to normal rapidly.¹⁹ Mouse-cat chimeric antibodies have also been tested against FHV-1 and FCV, with treated cats showing obviously reduced symptoms compared to untreated controls.²⁰

For feline coronavirus specifically, a neutralizing monoclonal antibody designated Ya-NT-1 was recently developed that targets type I FCoV, the serotype responsible for the vast majority of natural infections. It works at an unusual stage, blocking the virus after it has already attached to the cell but before it can complete entry.²¹ None of these antibody therapies are commercially available yet, but the pace of development suggests they could eventually complement antiviral drugs, particularly for acute infections where rapid virus clearance matters.

Polyprenyl Immunostimulant and the Non-Effusive FIP Niche

Before GS-441524 arrived, polyprenyl immunostimulant (PI) was one of the only treatments that showed any promise at all for FIP. It is not an antiviral in the traditional sense; rather, it stimulates the cat’s immune system to fight the virus. In a small initial report, two of three cats with dry-form FIP treated with PI were still alive two years after diagnosis, which was extraordinary at the time given that median survival for untreated dry FIP was measured in months.²² A larger field study found that PI appeared to increase survival times and improve quality of life in cats clinically diagnosed with dry FIP, though the authors acknowledged that a controlled study would be needed to verify the benefit.²³

Now that GS-441524 and molnupiravir exist with much stronger evidence, PI has been largely eclipsed for FIP treatment. It may still have a role as an adjunct or for cats who cannot tolerate other medications, but it is no longer the frontline option. Its story is a useful snapshot of how rapidly feline antiviral medicine has evolved: a treatment celebrated just a decade ago for keeping a handful of cats alive for months longer than expected now looks modest next to drugs achieving 85% cure rates.